Safety, pharmacokinetics and target engagement of novel RIPK1 inhibitor SAR443060 (DNL747) for neurodegenerative disorders: Randomized, placebo-controlled, double-blind phase I/Ib studies in healthy subjects and patients.
Saved in:
| Title: | Safety, pharmacokinetics and target engagement of novel RIPK1 inhibitor SAR443060 (DNL747) for neurodegenerative disorders: Randomized, placebo-controlled, double-blind phase I/Ib studies in healthy subjects and patients. |
|---|---|
| Authors: | Vissers MFJM; Centre for Human Drug Research, Leiden, The Netherlands.; Leiden University Medical Center, Leiden, The Netherlands., Heuberger JAAC; Centre for Human Drug Research, Leiden, The Netherlands., Groeneveld GJ; Centre for Human Drug Research, Leiden, The Netherlands.; Leiden University Medical Center, Leiden, The Netherlands., Oude Nijhuis J; Department of Neurology and Alzheimer Center, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands., De Deyn PP; Department of Neurology and Alzheimer Center, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.; Laboratory of Neurochemistry and Behavior, Department of Biomedical Sciences and Institute Born-Bunge, University of Antwerp, Antwerp, Belgium., Hadi S; PRA Health Sciences, Groningen, The Netherlands., Harris J; Denali Therapeutics Inc., South San Francisco, California, USA., Tsai RM; Denali Therapeutics Inc., South San Francisco, California, USA., Cruz-Herranz A; Denali Therapeutics Inc., South San Francisco, California, USA., Huang F; Denali Therapeutics Inc., South San Francisco, California, USA., Tong V; Denali Therapeutics Inc., South San Francisco, California, USA., Erickson R; Denali Therapeutics Inc., South San Francisco, California, USA., Zhu Y; Denali Therapeutics Inc., South San Francisco, California, USA., Scearce-Levie K; Denali Therapeutics Inc., South San Francisco, California, USA., Hsiao-Nakamoto J; Denali Therapeutics Inc., South San Francisco, California, USA., Tang X; Denali Therapeutics Inc., South San Francisco, California, USA., Chang M; Denali Therapeutics Inc., South San Francisco, California, USA., Fox BM; Denali Therapeutics Inc., South San Francisco, California, USA., Estrada AA; Denali Therapeutics Inc., South San Francisco, California, USA., Pomponio RJ; Sanofi Genzyme, Cambridge, Massachusetts, USA., Alonso-Alonso M; Sanofi Genzyme, Cambridge, Massachusetts, USA., Zilberstein M; Sanofi Genzyme, Cambridge, Massachusetts, USA., Atassi N; Sanofi Genzyme, Cambridge, Massachusetts, USA., Troyer MD; Denali Therapeutics Inc., South San Francisco, California, USA., Ho C; Denali Therapeutics Inc., South San Francisco, California, USA. |
| Source: | Clinical and translational science [Clin Transl Sci] 2022 Aug; Vol. 15 (8), pp. 2010-2023. Date of Electronic Publication: 2022 Jun 01. |
| Publication Type: | Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: WileyBlackwell Pub Country of Publication: United States NLM ID: 101474067 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1752-8062 (Electronic) Linking ISSN: 17528054 NLM ISO Abbreviation: Clin Transl Sci Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1752-8062 |
|---|---|
| DOI: | 10.1111/cts.13317 |
